Joseph Douglas Lyon - Apr 1, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Accounting & Technology Officer
Signature
/s/ Joseph Douglas Lyon
Stock symbol
CORT
Transactions as of
Apr 1, 2024
Transactions value $
-$7,329
Form type
4
Date filed
4/3/2024, 08:00 PM
Previous filing
Mar 5, 2024
Next filing
Apr 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $5.68K +500 +6.84% $11.35* 7.81K Apr 1, 2024 Direct F1
transaction CORT Common Stock Sale -$13K -500 -6.4% $26.01 7.31K Apr 1, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -500 -1.16% $0.00 42.7K Apr 1, 2024 Common Stock 500 $11.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements
F2 The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
F3 Fully exercisable.

Remarks:

Chief Accounting & Technology Officer